Payment overview · 2025
General Payments
$150.63
9 reported records · 5 companies
Healthcare provider profile · identity verified
Lakshmi Shankariah, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MT PLEASANT, MI · NPI 1174592893
Verified facts
What the public records show
CMS Open Payments records show Lakshmi Shankariah, MD received $150.63 in general payments during 2025 across 9 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.31 | 29.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.66 | 23.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.65 | 23.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.07 | 12.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.94 | 11.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $150.63 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $34.65 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.17 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 145 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 383 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 336 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 330 | 86 |
| Metformin Hcl | Metformin Hcl | 259 | 60 |
| Potassium Chloride | Potassium Chloride | 234 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 60 |
| Simvastatin | Simvastatin | 218 | 44 |
| Furosemide | Furosemide | 210 | 49 |
| Omeprazole | Omeprazole | 205 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 194 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 34 |
| Losartan Potassium | Losartan Potassium | 159 | 47 |
| Gabapentin | Gabapentin | 147 | 30 |
| Eliquis | Apixaban | 145 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 38 |
| Allopurinol | Allopurinol | 134 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 108 | 27 |
| Tramadol Hcl | Tramadol Hcl | 102 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 22 |
| Atenolol | Atenolol | 80 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 16 |
| Farxiga | Dapagliflozin Propanediol | 77 | 18 |
| Prednisone | Prednisone | 75 | 43 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 18 |
| Baclofen | Baclofen | 68 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 68 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 65 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 16 |
| Alprazolam | Alprazolam | 61 | suppressed |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Bumetanide | Bumetanide | 58 | 18 |
| Enalapril Maleate | Enalapril Maleate | 57 | 13 |
| Finasteride | Finasteride | 56 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 23 |
| Spironolactone | Spironolactone | 56 | 13 |
| Donepezil Hcl | Donepezil Hcl | 55 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 55 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 17 |
| Pregabalin | Pregabalin | 53 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 37 |
| Memantine Hcl | Memantine Hcl | 49 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 12 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Lorazepam | Lorazepam | 43 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 42 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 11 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | 11 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | suppressed |
| Fentanyl | Fentanyl | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 18 |
| Famotidine | Famotidine | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Digoxin | Digoxin | 30 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 20 |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 14 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Sulfasalazine | Sulfasalazine | 17 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Pulmicort Flexhaler | Budesonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $150.63 · 9 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ELIQUIS, FARXIGA, OTEZLA, Ozempic, REPATHA, Rybelsus, The Cologuard Plus Collection Kit | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error